MBOT Microbot Medical Inc.
USHealthcareAs of 2026-07-10 16:00
Why MBOT matters now
Microbot Medical Inc. (MBOT) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.89 with +1.61% on the session and $86.1M in market capitalization; recent performance reads 1-month +7.51% and YTD -7.00%.
The latest financial table shown here is Q1 2026, with revenue of $105.0K, net income of $-3.7M, and EPS of $-0.05. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -18.1%.
The latest indexable market news headline is "Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $4.00; recent insider activity includes Laxminarain Prattipati filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.69
P/S
807.25
EV/EBITDA
-5.79
DCF Value
$0.07
FCF Yield
-18.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-9.5%
Operating Margin
-15278.1%
Net Margin
-13535.2%
ROE
-21.8%
ROA
-18.2%
ROIC
-21.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $105.0K | $-3.7M | $-0.05 |
| Q4 2025 | $0.00 | $-3.5M | $-0.05 |
| FY 2025 | $0.00 | $-13.1M | $-0.29 |
| Q3 2025 | $0.00 | $-3.6M | $-0.07 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$4.00
Target (Median)
$4.00
Target Range
$4.00 - $4.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
1.04
Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.